Enoxaparin sodium
Lovenox, Thorinane (enoxaparin sodium) is an oligosaccharide pharmaceutical. Enoxaparin sodium was first approved as Lovenox (preservative free) on 1993-03-29. It is used to treat myocardial infarction, postoperative complications, pulmonary embolism, thromboembolism, and thrombophlebitis amongst others in the USA. It has been approved in Europe to treat venous thromboembolism. The pharmaceutical is active against antithrombin-III.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Lovenox (generic drugs available since 2010-07-23)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| enoxaparin sodium | ANDA | 2023-06-16 |
| lovenox | New Drug Application | 2022-12-30 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| myocardial infarction | EFO_0000612 | D009203 | I21 |
| postoperative complications | — | D011183 | — |
| pulmonary embolism | EFO_0003827 | D011655 | I26 |
| thromboembolism | HP_0001907 | D013923 | — |
| thrombophlebitis | HP_0004418 | D013924 | — |
| unstable angina | EFO_1000985 | D000789 | I20.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J1650 | Injection, enoxaparin sodium, 10 mg |
Clinical
Clinical Trials
297 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | 5 | 19 | 28 | 15 | 3 | 66 |
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | 5 | 15 | 15 | 18 | 10 | 59 |
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | 6 | 5 | 10 | 8 | 5 | 31 |
| Covid-19 | D000086382 | U07.1 | — | 4 | 11 | 7 | 5 | 27 | |
| Thromboembolism | D013923 | HP_0001907 | — | 4 | 5 | 3 | 5 | 17 | |
| Thrombosis | D013927 | 1 | 1 | 2 | 5 | 3 | 12 | ||
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 1 | 6 | 2 | — | 8 |
| Acute coronary syndrome | D054058 | EFO_0005672 | 2 | — | — | 5 | 1 | 8 | |
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | — | — | 3 | 2 | 6 |
| Unstable angina | D000789 | EFO_1000985 | I20.0 | — | — | 2 | 2 | 1 | 5 |
Show 41 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | — | — | 3 | — | 3 | 6 | |
| Replacement arthroplasty knee | D019645 | — | 4 | 2 | — | — | 6 | ||
| Replacement arthroplasty hip | D019644 | — | 3 | 3 | — | — | 5 | ||
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | — | — | 3 | — | 1 | 4 |
| Fetal growth retardation | D005317 | EFO_0000495 | — | — | 2 | — | 1 | 3 | |
| Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | — | 2 | — | — | 2 |
| Coagulation protein disorders | D020147 | — | — | 1 | — | 1 | 2 | ||
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | — | — | 2 | ||
| Small cell lung carcinoma | D055752 | — | 1 | 1 | — | — | 2 | ||
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | 1 | — | 1 | 2 |
Show 12 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 5 | 2 | — | — | 1 | 7 | ||
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | — | — | 1 | 2 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 2 | — | — | — | 2 |
| Lymphoma | D008223 | C85.9 | 1 | 1 | — | — | 1 | 2 | |
| Morbid obesity | D009767 | EFO_0001074 | 2 | 1 | — | — | — | 2 | |
| Female genital neoplasms | D005833 | — | 1 | — | — | — | 1 | ||
| Embolism and thrombosis | D016769 | — | 1 | — | — | — | 1 | ||
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | — | — | — | 1 |
| Virus diseases | D014777 | B34 | — | 1 | — | — | — | 1 | |
| Esophageal neoplasms | D004938 | C15 | — | 1 | — | — | — | 1 |
Show 7 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | — | — | — | 1 | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombophilia | D019851 | D68.59 | — | — | — | — | 3 | 3 | |
| Traumatic intracranial hemorrhage | D020198 | — | — | — | — | 2 | 2 | ||
| Fertilization in vitro | D005307 | — | — | — | — | 2 | 2 | ||
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | — | — | 1 | 1 |
| Non-st elevated myocardial infarction | D000072658 | — | — | — | — | 1 | 1 | ||
| Soft tissue neoplasms | D012983 | — | — | — | — | 1 | 1 | ||
| Coronary artery bypass | D001026 | EFO_0003776 | — | — | — | — | 1 | 1 | |
| Infusion pumps | D007260 | — | — | — | — | 1 | 1 | ||
| Meningioma | D008579 | EFO_0003098 | D32.9 | — | — | — | — | 1 | 1 |
| Abruptio placentae | D000037 | EFO_1001754 | O45 | — | — | — | — | 1 | 1 |
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ENOXAPARIN SODIUM |
| INN | enoxaparin sodium |
| Description | Enoxaparin sodium, sold under the brand name Lovenox among others, is an anticoagulant medication (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) including during pregnancy and following certain types of surgery. It is also used in those with acute coronary syndrome (ACS) and heart attacks. It is given by injection just under the skin or into a vein. It is also used during hemodialysis.
|
| Classification | Oligosaccharide |
| Drug class | heparin derivatives and low molecular weight (or depolymerized) heparins |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 679809-58-6 |
| RxCUI | 221095 |
| ChEMBL ID | CHEMBL1201476 |
| ChEBI ID | — |
| PubChem CID | 772 |
| DrugBank | DBSALT002813 |
| UNII ID | 8NZ41MIK1O (ChemIDplus, GSRS) |
Target
Agency Approved
SERPINC1
SERPINC1
Organism
Homo sapiens
Gene name
SERPINC1
Gene synonyms
AT3
NCBI Gene ID
Protein name
antithrombin-III
Protein synonyms
serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1, Serpin C1, serpin peptidase inhibitor clade C member 1, serpin peptidase inhibitor, clade C (antithrombin), member 1
Uniprot ID
Mouse ortholog
Serpinc1 (11905)
antithrombin-III (P32261)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Lovenox - Sanofi
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 18,842 documents
View more details
Safety
Black-box Warning
Black-box warning for: Enoxaparin sodium, Lovenox
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,378 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more